CSS PEPR MIE AAP 2024
Last updated on 24 April 2025
Scope
Sectoral Scientific Committee (CSS) established as part of the 2024 call for proposal of the Emerging Infectious Diseases Priority Research Programme and Equipment (PEPR MIE AAP 2024)
Section 1
Accelerating the acquisition of fundamental knowledge on emerging infectious diseases
Chair
Björn MEYER
Otto von Guericke University Magdeburg – Germany
Co-chair
Valeria LULLA
University of Cambridge – United Kingdom
Membres
Lark L. Coffey
(University of California, Davis – USA)
Christian Conrad
(BIH Digital Health Center, Charity – Germany)
Ousmane Faye
(Institut Pasteur of Dakar – Senegal)
Andrés Finzi
(University of Montreal – Canada)
Natalia Freund
(Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine – Israel)
Nadia Izadi-Pruneyre
(CNRS UMR3528, Institut Pasteur – France)
Laurent Jacob
(LBBE Laboratory, University Lyon 1 – France)
Nadine LAGUETTE
(IGH (UPR 1142), CNRS – France)
Hugo Léon
(Mosquito Control Laboratory, QIMR Berghofer Medical Research Institute – Australia)
Carlos Maluquer de Motes
( University of Surrey – United Kingdom)
Arnaud Marchant
(Institute for Medical Immunology, Université libre de Bruxelles – Belgium)
Kevin Maringer
(The Pirbright Institute, Surrey – United Kingdom)
Sarah Merkling
(CNRS UMR 2000, Institut Pasteur – France)
Ali Mirazami
(Department of Laboratory Medicine, Karolinska Institute – Sweden)
Anna Overby
(Umeå University – Sweden)
Mathilde Richard
(Erasmus MC, Department of Viroscience, Associate Professor – Netherlands)
Julien Riou
(Institute of Social and Preventive Medicine (ISPM), University of Bern – Switzerland)
Esther Schnettler
(Bernhard Nocht Institute for Tropical Medicine / University of Hamburg – Germany)
Avinash Shenoy
(Francis Crick Institute, London – United Kingdom)
Adithya Sridhar
(Amsterdam UMC – Netherlands)
Abdou Rachid Thiam
( ENS Paris, CNRS, Physics Laboratory, Biological Emulsions Team – France)
Elisa Vicenzi
(San Raffaele Scientific Institute, Viral Pathogens and Biosafety Unit – Italy)
Section 2
Promoting innovation and developing new treatments, vaccines and other prevention, diagnostic and surveillance tools for emerging infectious diseases.
Présidence
Nathalie Garçon
Chief Executive Officer (CEO) and Chief Scientific Officer (CSO) of Bioaster, France
Membres
Emanuele Andreano
(Toscana Life Science / GSK, Sienne, Italy)
Arinjay Banerjee
(University of Saskatchewan, Saskatoon, Viral Vaccine Development Group – Canada)
Jérôme Courcambeck
(Genoscience-Pharma – France)
Laura Del Rio
(University of Murcia – Spain)
Arnaud Didierlaurent
(Department of Pathology and Immunology, Geneva University Hospitals – Switzerland)
Anna Niarakis
(University of Évry Val d’Essonne and University of Toulouse III Paul Sabatier – France)
Didier Rognan
(Laboratory of Therapeutic Innovation – UMR 7200 – University of Strasbourg – France)
Nicolas Sapay
(Grand Lyon, France)
Saranya Sridhar
(Global Clinical Development, Vaccines R&D, Sanofi Pasteur / Imperial College London – United Kingdom)
Christophe Vedrine
(Bioaster, Head of the Microsystems / Microfluidics Unit – France)
Nuria Verdaguer
(Institute of Molecular Biology of Barcelona (CSIC) – Spain)
Emmanuelle Vigne
(SANOFI, France)
Manfred Weidmann
(Independent Expert – Germany)
Winfried Weissenhorn
(IBS-CEA Grenoble, France)
Florian Wimmers
(University of Tübingen – Germany)
Section 3
Enabling public policies and society to cope with epidemic crises
Présidence
Catherine Hankins
McGill University, Department of Epidemiology, Biostatistics and Occupational Health – Canada
Membres
Anne Cori
(Imperial College London, Faculty of Medicine, School of Public Health – United Kingdom)
Rosemary Dray-Spira
(EPI-PHARE (ANSM-CNAM), France)
Thomas Druetz
(University of Montreal, School of Public Health – Department of Social and Preventive Medicine – Canada)
Simon Ducarroz
(IPLESP / Inserm UMR_S 1136 – France)
Marisa Peyre
(Cirad, France)